What is the Return on Assets (ROA) of Arvinas this year?
The Return on Assets (ROA) of Arvinas is -0.28 undefined this year.
Arvinas ROA 2024
Arvinas ROA
-0.28
Ticker
ARVN
ISIN
US04335A1051
WKN
A2N6VP
In 2024, Arvinas's return on assets (ROA) was -0.28, a 26.45% increase from the -0.22 ROA in the previous year.
Arvinas Aktienanalyse
What does Arvinas do?
Arvinas Inc. is a biopharmaceutical company based in New Haven, Connecticut, USA. It was founded in 2013 by Dr. Craig Crews, who also serves as a scientific advisor to the company. The company's mission is to develop innovative therapies based on Proteolysis-Targeting Technology (PROTAC). This technology uses artificially engineered molecules to identify and mark specific proteins in the body, which are then degraded by the body's own enzymes. This approach can treat diseases caused by misfolded or overexpressed proteins. Arvinas' business model is to develop multiple drug candidates based on this platform. The company collaborates with leading academic institutions and biotechnology companies to identify targets that can be reached using PROTAC technology. Additionally, the company has a proprietary pipeline of drug candidates in various stages of clinical development. Arvinas operates in several therapeutic areas, including cancer, immunology, and metabolic disorders. Their drug candidates include ARV-110, a PROTAC targeting the androgen receptor protein (AR), which is a potential therapy for patients with resistant prostate cancer. Similarly, Arvinas' other drug candidates target specific proteins associated with certain diseases. Another drug from the company is ARV-471, an orally administered degrader targeting the estrogen receptor alpha (ERa), which plays a role in breast cancer. ARV-471 is a potential therapy for patients with rare subtypes of breast cancer. Arvinas also has partnerships in various areas of drug development. For example, in collaboration with Pfizer, they are developing ARV-411, a PROTAC targeting the menin-1 protein, which is involved in acute myeloid leukemia. Arvinas also has a partnership with Genentech, a subsidiary of Roche, for the use of PROTAC in the treatment of cancer. Overall, Arvinas is an innovative biopharmaceutical company based on Proteolysis-Targeting Technology, focusing on the development of comprehensive therapeutic approaches. With numerous partnerships and a diverse pipeline, the company is well-positioned to play a significant role in drug development. Arvinas ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding Arvinas's Return on Assets (ROA)
Arvinas's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Arvinas's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Arvinas's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Arvinas’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Arvinas stock
What was the ROA of Arvinas compared to the previous year?
The ROA of Arvinas has increased by 26.45% compared to the previous year.
What consequences do high ROA have for investors of Arvinas?
A high ROA is advantageous for investors of Arvinas, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Arvinas?
A low ROA can be unfavorable for investors of Arvinas as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Arvinas affect the company?
An increase in ROA of Arvinas can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Arvinas impact the company?
A reduction in the ROA of Arvinas can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Arvinas?
Some factors that can influence the ROA of Arvinas include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Arvinas important for investors?
The ROA of Arvinas is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Arvinas take to improve ROA?
To improve ROA, Arvinas can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Arvinas pay?
Over the past 12 months, Arvinas paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arvinas is expected to pay a dividend of 0 USD.
What is the dividend yield of Arvinas?
The current dividend yield of Arvinas is .
When does Arvinas pay dividends?
Arvinas pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Arvinas?
Arvinas paid dividends every year for the past 0 years.
What is the dividend of Arvinas?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Arvinas located?
Arvinas is assigned to the 'Health' sector.
Wann musste ich die Aktien von Arvinas kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Arvinas from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.
When did Arvinas pay the last dividend?
The last dividend was paid out on 10/4/2024.
What was the dividend of Arvinas in the year 2023?
In the year 2023, Arvinas distributed 0 USD as dividends.
In which currency does Arvinas pay out the dividend?
The dividends of Arvinas are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Arvinas
Our stock analysis for Arvinas Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arvinas Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
